BBR Partners LLC Increases Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

BBR Partners LLC boosted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 100.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 40,000 shares of the company's stock after acquiring an additional 20,000 shares during the quarter. BBR Partners LLC owned about 0.15% of LENZ Therapeutics worth $950,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. purchased a new stake in LENZ Therapeutics in the first quarter valued at $4,621,000. American International Group Inc. purchased a new stake in shares of LENZ Therapeutics in the first quarter worth about $44,000. Jacobs Levy Equity Management Inc. acquired a new stake in LENZ Therapeutics during the first quarter worth about $830,000. Wealth Enhancement Advisory Services LLC purchased a new position in LENZ Therapeutics during the second quarter valued at approximately $1,437,000. Finally, Bank of New York Mellon Corp lifted its holdings in LENZ Therapeutics by 255.4% in the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company's stock valued at $687,000 after acquiring an additional 28,556 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Up 2.9 %

Shares of LENZ traded up $1.05 during mid-day trading on Thursday, hitting $37.30. 104,028 shares of the company were exchanged, compared to its average volume of 136,494. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93. The company has a 50 day moving average of $28.20 and a 200-day moving average of $22.98.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. During the same period last year, the firm posted ($1.33) EPS. Sell-side analysts expect that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LENZ has been the topic of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, November 7th. William Blair upgraded LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Raymond James initiated coverage on LENZ Therapeutics in a report on Friday, September 27th. They issued an "outperform" rating and a $37.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.